Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
Crossref DOI link: https://doi.org/10.1007/s00280-016-3124-5
Published Online: 2016-08-23
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Swaisland, Helen
Plummer, Ruth
So, Karen
Garnett, Sally
Bannister, Wendy
Fabre, Marc-Antoine
Dota, Corina
Fielding, Anitra
Funding for this research was provided by:
AstraZeneca
License valid from 2016-08-23